HomeToday’s HighlightsThe Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals. The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals. Today’s Highlights April 8, 2019 The Amgen/Novartis Story In May 2018 Amgen (AMGN) & Novartis (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Alder BioPharmaceuticals (ALDR), Amgen (AMGN), Novartis (NVS) April 8, 2019 Tweet Pin It Other Articles BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions March 24, 2025 0 FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® – A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits March 21, 2025 0 Two Companies: Pyxis Oncology Financial Results and Sarepta Therapeutics Unwarranted Selloff March 18, 2025 0 A Little About the Stock Market and Some News from Johnson & Johnson March 10, 2025 0